A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of Response in Patients With Hodgkin's Lymphoma Who Are at Risk for Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant

Inclusion Criteria:

1. Patient age is greater than or equal to 18 years

2. Patient has a history of histologically confirmed classical HL (i.e. Nodular
sclerosing (NSHL), Mixed-cellularity (MCHL), Lymphocyte-rich (LRHL), Lymphocyte
depleted (LDHL))

3. Patient has achieved a complete response by CT/MRI scan within 9 weeks (± 1 week)
from the day of their first autologous peripheral blood/ bone marrow stem cell
transfusion (AHSCT) following HDT. Complete response is defined as:

Normalization of all nodes and lesions compared to pre-transplant scan performed
prior to salvage therapy for relapse. Any residual abnormal masses on the post
transplant CT/MRI must be metabolically inactive on a PET scan.

4. Patient has at least one of the following factors that places them at risk for
relapse:

- Primary refractory disease (including relapse in ≤ 3 months of completion of 1st
line treatment)

- First relapse >3 but <12 months from last dose of 1st line treatment

- Multiple relapses (prior to transplant)

- Stage III/IV disease (at relapse, prior to transplant)

- Hemoglobin <10.5 gm/dL (at relapse, prior to transplant)

Exclusion Criteria:

Patient has been treated with allogeneic transplant 2. Patient has received any
anti-lymphoma therapy after AHSCT including but not limited to:

- chemotherapy prior to start of study

- biologic immunotherapy including monoclonal antibodies or experimental therapy prior
to start of study

- radiation therapy 3. Patient has not recovered from reversible toxicity due to any
prior therapies (e.g. returned to baseline or Grade ≤1) except for hematological
laboratory parameters Note: Patient does not meet this criteria if the toxicity is
stable and irreversible, and there is no evidence that panobinostat causes a similar
toxicity 4. Patient has received prior treatment with DAC inhibitors including
panobinostat

Other protocol-defined inclusion/exclusion criteria may apply